Drugs / Prolectin-M
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05733780 | Sep → Dec 2023 | COVID-19 | Bioxytran Inc. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Prolectin-M | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05733780 ↗ |
| Action | Inhibit | “a galectin antagonist” NCT05733780 ↗ |
| Modality | Other / unclassified | “ProLectin M is an orally administered polysaccharide.” NCT05733780 ↗ |
| Route | Oral | “orally administered polysaccharide” NCT05733780 ↗ |